Halozyme Therapeutics, Inc. (HALO)
108.64
+0.47
(+0.43%)
USD |
NASDAQ |
Aug 24, 16:00
108.64
0.00 (0.00%)
After-Hours: 19:20
Halozyme Therapeutics Debt to Equity Ratio : 14.95 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 14.95 |
| March 31, 2026 | 9.764 |
| December 31, 2025 | 44.60 |
| September 30, 2025 | 2.998 |
| June 30, 2025 | 4.535 |
| March 31, 2025 | 3.126 |
| December 31, 2024 | 4.223 |
| September 30, 2024 | 3.323 |
| June 30, 2024 | 5.191 |
| March 31, 2024 | 8.441 |
| December 31, 2023 | 17.89 |
| September 30, 2023 | 6.010 |
| June 30, 2023 | 9.905 |
| March 31, 2023 | 22.69 |
| December 31, 2022 | 8.87 |
| September 30, 2022 | 15.51 |
| June 30, 2022 | 4.251 |
| March 31, 2022 | 3.372 |
| December 31, 2021 | 4.451 |
| September 30, 2021 | 3.109 |
| June 30, 2021 | 7.305 |
| March 31, 2021 | 12.93 |
| December 31, 2020 | 2.630 |
| September 30, 2020 | 3.984 |
| June 30, 2020 | 3.711 |
| Date | Value |
|---|---|
| March 31, 2020 | 6.710 |
| December 31, 2019 | 4.387 |
| September 30, 2019 | 0.2602 |
| June 30, 2019 | 0.3267 |
| March 31, 2019 | 0.4053 |
| December 31, 2018 | 0.5078 |
| September 30, 2018 | 0.6109 |
| June 30, 2018 | 0.6513 |
| March 31, 2018 | 0.6985 |
| December 31, 2017 | 0.9711 |
| September 30, 2017 | 2.858 |
| June 30, 2017 | 3.628 |
| March 31, 2017 | -3.659 |
| December 31, 2016 | -6.669 |
| September 30, 2016 | -17.69 |
| June 30, 2016 | 20.98 |
| March 31, 2016 | 6.651 |
| December 31, 2015 | 1.159 |
| September 30, 2015 | 1.566 |
| June 30, 2015 | 0.9905 |
| March 31, 2015 | 1.324 |
| December 31, 2014 | 1.206 |
| September 30, 2014 | 1.248 |
| June 30, 2014 | 0.9008 |
| March 31, 2014 | 0.746 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Incyte Corp. | 0.006 |
| Neurocrine Biosciences, Inc. | 0.1088 |
| AVITA Medical, Inc. | -1.742 |
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 4.903 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 2.577B |
| Total Liabilities (Quarterly) | 2.434B |
| Shareholders Equity (Quarterly) | 143.54M |
| Current Ratio | 2.709 |
| Net Debt Paydown Yield | -1.43% |